Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The stable introduction of a functional beta-globin gene in haematopoietic stem cells could be a powerful approach to treat beta-thalassaemia and sickle-cell disease. Genetic approaches aiming to increase normal beta-globin expression in the progeny of autologous haematopoietic stem cells might circumvent the limitations and risks of allogeneic cell transplants. However, low-level expression, position effects and transcriptional silencing hampered the effectiveness of viral transduction of the human beta-globin gene when it was linked to minimal regulatory sequences. Here we show that the use of recombinant lentiviruses enables efficient transfer and faithful integration of the human beta-globin gene together with large segments of its locus control region. In long-term recipients of unselected transduced bone marrow cells, tetramers of two murine alpha-globin and two human betaA-globin molecules account for up to 13% of total haemoglobin in mature red cells of normal mice. In beta-thalassaemic heterozygous mice higher percentages are obtained (17% to 24%), which are sufficient to ameliorate anaemia and red cell morphology. Such levels should be of therapeutic benefit in patients with severe defects in haemoglobin production.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After establishing that β-globin lentiviral vectors had successfully corrected models of β-thalassemia and sickle cell disease in mice, 17,18 we initiated a human clinical study of ex vivo gene therapy for the β-hemoglobinopathies”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [17]
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“, referred to as the locus control region (LCR), are linked to the globin gen”
BackgroundMalim, M. H., Hauber, J., Le, S.-Y., Maizel, J. V., & Cullen, B. R. (1989) · Nature · doi:10.1038/338254a0 · Cited by 1,280 · cited 1×
“Here we report how these problems may be overcome by using vectors derived from human immunodeficiency virus 1, a retrovirus that has the ability to regulate packaging of unspliced viral genome”
Hematology of Infancy and Childhood.
(1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-587_2 · Cited by 892
The Molecular Basis of Blood Diseases.
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-6-950_3 · Cited by 632
Miyoshi, H., Smith, K. A., Mosier, D. E., Verma, I. M., & Torbett, B. E. (1999) · Science · doi:10.1126/science.283.5402.682 · Cited by 624
The "beta-like-globin" gene domain in human erythroid cells.
Tuan, D., Solomon, W., Li, Q., & London, I. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6384 · Cited by 601 · cited 1×
“The same outcome prevails in transgenic mice unless genomic elements encompassing DNase I hypersensitive sites (HS) located 60 kilobases (kb) upstream of the human β-globin gen”
BackgroundLooping versus linking: toward a model for long-distance gene activation
Bulger, M., & Groudine, M. (1999) · Genes & Development · doi:10.1101/gad.13.19.2465 · Cited by 484
Raj, S. R., Chen, S. R. W., Sheldon, R. S., Shah, A. N., Kantharia, B. K., Salzer, U., Grimbacher, B., Leung, A. K. C., Kamat, D., Kolovou, G. D., et al. (2009) · Encyclopedia of Molecular Mechanisms of Disease · doi:10.1007/978-3-540-29676-8_1731 · Cited by 475
Cited by
Items 401–500 of 622
Differences of globin transgene expression in stably transfected cell lines and transgenic mice
Li, Q., Emery, D. W., Han, H., Sun, J., Yu, M., & Stamatoyannopoulos, G. (2004) · Blood · doi:10.1182/blood-2004-03-0987 · Cited by 10
Gene therapy for the hemophilias
Walsh, C. (2002) · Current Opinion in Pediatrics · doi:10.1097/00008480-200202000-00003 · Cited by 10
Hayakawa, J., Ueda, T., Lisowski, L., Hsieh, M. M., Washington, K., Phang, O., Metzger, M., Krouse, A., Donahue, R. E., Sadelain, M., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.186 · Cited by 9
“…(3.2kb) spanning HS2, 3, and 4, efficient gene transfer and therapeutic human b -globin gene expression in murine model was demonstrated, allowing for the first time regulated human b -globin expression sufficient to revert the phenotype in a murine model of b -thalassemia (May et al. , 2000).”
InfluentialSelf-citationEpigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic Targets
Vasiloudis, N.-I., Paschoudi, K., Beta, C., Georgolopoulos, G., & Psatha, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136342 · Cited by 9
“In the most recent version of this vector, Lentiglobin BB305 (created by Bluebird Bio-BBB), the cHS4 element was excluded, resulting in higher vector titers and improved gene transfer efficiency, enhancing its clinical utility [169].”
Hart, K. L., Liu, B., Brown, D., Campo-Fernández, B., Tam, K., Orr, K., Hollis, R. P., Brendel, C., Williams, D. A., & Kohn, D. B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101254 · Cited by 9
Ouyang, W., Dong, G., Zhao, W., Li, J., Zhou, Z., Yang, G., Liu, R., Li, Y., Zhang, Q., Du, X., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.204 · Cited by 9
Guo, C., & Jin, X. (2006) · Cancer Investigation · doi:10.1080/07357900600981299 · Cited by 9
Sabatino, D. E., Seidel, N. E., Cline, A. P., Anderson, S. M., Gallagher, P. G., & Bodine, D. M. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03595.x · Cited by 9
Fischer, A. (2000) · EMBO Reports · doi:10.1093/embo-reports/kvd085 · Cited by 9
“Sustained transduction of quiescent cells has also been demonstrated by using the xenogenic NOD/SCID transplantation model (Miyoshi et al., 1999).”
MethodSafety and efficacy in retrovirally modified haematopoietic cell therapy
Li, Z., Modlich, U., & Baum, C. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.05.009 · Cited by 9
Kang, S.-H. L., Levings, P. P., Andersen, F. F., Laipis, P. J., Berns, K. I., Zori, R., & Bungert, J. (2004) · Genes to Cells · doi:10.1111/j.1365-2443.2004.00788.x · Cited by 9
Gene therapy for sickle cell disease
Olowoyeye, A., & Okwundu, C. I. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007652.pub4 · Cited by 9
Gene Therapy for Homozygous β -thalassemia. Is it a Reality?
Boulad, F., Rivière, I., & Sadelain, M. (2009) · Hemoglobin · doi:10.3109/03630260903351866 · Cited by 8
Self-citationOf mice and men: From hematopoiesis in mouse models to curative gene therapy for sickle cell disease
Makani, J., & Luzzatto, L. (2022) · Cell · doi:10.1016/j.cell.2022.03.031 · Cited by 8
Self-citationStem cells: An insight into the therapeutic aspects from medical and dental perspectives
Sivakumar, M., Dineshshankar, J., Sunil, P., Nirmal, R., Sathiyajeeva, J., Saravanan, B., & Eagappan, S. (2015) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.163453 · Cited by 8
Recent advances in the management of Thalassaemia: A Review Update
Sarker, N. R., Ghosh, A. K., Saha, S. K., & Shahriar, A. (2017) · Journal of Shaheed Suhrawardy Medical College · doi:10.3329/jssmc.v6i1.31490 · Cited by 8
Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C. F., Kustikova, O. S., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-190 · Cited by 8
Testa, A., Lotti, F., Cairns, L., Grande, A., Ottolenghi, S., Ferrari, G., & Ronchi, A. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313638200 · Cited by 8
Larochelle, A., Peng, K.-W., & Russell, S. J. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-56114-6_7 · Cited by 8
Mishra, S., Wang, X., Smiley, N., Xia, P., Hong, C. M., Senadheera, D., Bui, K. C., & Lutzko, C. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0235oc · Cited by 7
Lahiji, A., Kučerová-Levisohn, M., Lovett, J., Holmes, R., Zúñiga‐Pflücker, J. C., & Ortiz, B. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300521 · Cited by 7
Papapetrou, E. P. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_9 · Cited by 7
Cellular and animal models for the investigation of β-thalassemia
Nai, A., Cordero-Sánchez, C., Tanzi, E., Pagani, A., Silvestri, L., & Modica, S. M. D. (2023) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2023.102761 · Cited by 7
Moosig, F., Reinhold‐Keller, E., Holl‐Ulrich, K., Feller, A. C., Bley, T. A., Holle, J. U., Zwerina, J., Lamprecht, P., Dalhoff, K., Venhoff, N., et al. (2012) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-012-0988-6 · Cited by 7
Sato, T., Ikeda, M., Yotsumoto, S., Shimada, Y., Higuchi, T., Kobayashi, H., Fukuda, T., Ohashi, T., Suda, T., & Ohteki, T. (2013) · Blood · doi:10.1182/blood-2012-07-443713 · Cited by 7
δ‐Globin Gene Structure and Expression in the K562 Cell Line
Poddie, D., Marongiu, M. F., Ferrari, S. C., Porcu, S., & Ristaldi, M. S. (2003) · Hemoglobin · doi:10.1081/hem-120026046 · Cited by 7
In Vivo and Ex Vivo Gene Transfer in Thymocytes and Thymocyte Precursors
Adjali, O., Montel‐Hagen, A., Swainson, L. A., Marty, S., Vicente, R., Mongellaz, C., Jacquet, C., Zimmermann, V. S., & Taylor, N. N. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-409-4_13 · Cited by 7
Terapia génica: opción terapéutica para neoplasias, infecciones y enfermedades monogénicas
Cavagnari, B. M. (2011) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2011.326 · Cited by 7
Phyto-Medicine in Gene(s) Targeting Future Direction for Sickle Cell Disease Management
Alli, L. A., & Okoh, M. P. (2016) · Hereditary Genetics · doi:10.4172/2161-1041.1000169 · Cited by 7
Gough, P. J., & Raines, E. W. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00010 · Cited by 7
Tolerogenic property of MHC class I and class II molecules: lessons from a gene therapy approach
LeGuern, C. (2007) · Frontiers in bioscience · doi:10.2741/2301 · Cited by 7
Gene therapy for sickle cell disease marches on
Bodine, D. M. (2003) · Blood · doi:10.1182/blood-2003-09-3305 · Cited by 7
Guo, C., Li, Y., & Jin, X. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0144-y · Cited by 7
Ex Vivo Gene and Cell Therapy in Hematopoietic Stem Cells
Petrova, I. O., & Smirnikhina, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311466 · Cited by 6
“The first vector, TNS9, carried a β -globin cassette including introns with an intron 2 internal deletion under control of an endogenous β -globin promoter and a 3.2 kb locus control region (LCR) element (HS2, HS3, and HS4) [46].”
InfluentialYannaki, E., Psatha, N., Παπαδοπούλου, Α., Athanasopoulos, T., Gravanis, A., Roubelakis, M. G., Tsirigotis, P. D., Anagnostopoulos, Α., Anagnou, N. P., & Vassilopoulos, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.196 · Cited by 6
The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy forβ-Thalassemia
Drakopoulou, E., Papanikolaou, E., & Anagnou, N. P. (2011) · Stem Cells International · doi:10.4061/2011/987980 · Cited by 6
Novel Therapy Approaches in β-Thalassemia Syndromes — A Role of Genetic Modifiers
Pavlović, S., Ugrin, M., & Stojiljković, M. (2015) · InTech eBooks · doi:10.5772/61023 · Cited by 6
Varganov, Y., Amosova, O., & Fresco, J. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302850 · Cited by 6
“dtd"[ ]> Introduction The prevailing approach to gene therapy for diseases due to point mutations has been to try to add the wild-type antecedent of the mutant gene using a viral vector that integrates into the genome”
BackgroundGene therapy for sickle cell disease
Olowoyeye, A., & Okwundu, C. I. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007652.pub3 · Cited by 6
Wright, J., Alberts, B., Hood, A. J. M., Nogueira, C., Miskolczi, Z., Vieira, C. R., Chipchase, D., Lamont, C. M., Goodyear, O. C., Moyce, L. J., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e43732 · Cited by 5
Rossi, M. (2023) · Science Reviews Biology · doi:10.57098/scirevs.biology.2.3.3 · Cited by 5
Transgene expression from CpG-reduced lentiviral gene delivery vectors in vitro
Low, P. T., Lai, M. I., Ngai, S. C., & Abdullah, S. (2013) · Gene · doi:10.1016/j.gene.2013.09.075 · Cited by 5
Polymers in Drug Delivery: Concepts, Developments and Potential
Chen, R. (2013) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-6010-3_1 · Cited by 5
Síndromes talasémicos. Nuevos conceptos y estado actual del conocimiento en Costa Rica
Renauld, G. S., & Rodríguez-Romero, W. (2009) · Acta Médica Costarricense · doi:10.51481/amc.v48i4.270 · Cited by 5
Becker, P. S. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10131 · Cited by 5
“…to circumvent the difficulty in obtaining a high proportion of cycling stem cells while preserving the ability to self-renew and maintain multilineage potential, many investigators have been utilizing lentiviral vectors which have the advantage of infecting nondividing cells [May et al., 2000].”
BackgroundCurrent and emerging drug treatment strategies to tackle sickle cell anemia
Persaud, Y., Leonard, A. K., & Rai, P. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2379260 · Cited by 4
Virus-based vectors for gene expression in mammalian cells: Lentiviruses
Gasmi, M., & Wong‐Staal, F. (2003) · New comprehensive biochemistry · doi:10.1016/s0167-7306(03)38015-9 · Cited by 4
Future Perspectives for the Treatment of Sickle Cell Anemia
Nottage, K. A., Estepp, J. H., & Hankins, J. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-06713-1_16 · Cited by 4
Sickle cells produce functional immune modulators and cytotoxics
Sun, C., Wu, L.-C., Knopick, P. L., Bradley, D. S., Townes, T. M., & Terman, D. S. (2017) · American Journal of Hematology · doi:10.1002/ajh.24836 · Cited by 4
Hemoglobin Gene Therapy for β-Thalassemia
Bank, A. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.08.002 · Cited by 4
Kaufman, R. M., Lu, Z. H., Behl, R., Holt, J. M., Ackers, G. K., & Ley, T. J. (2001) · Blood · doi:10.1182/blood.v98.1.65 · Cited by 4
Gene Therapy for Hemoglobinopathies
Dong, A., Breda, L., & Rivella, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00012-9 · Cited by 4
Self-citationEvaluation of Optimal Expression Cassette in Retrovirus Vector for β-Thalassemia Gene Therapy
Dong, W.-J., Li, B., Liu, D., Zu, Z.-X., Li, J., Hao, D., Liu, G., Guo, Z.-C., & Liang, C. (2003) · Molecular Biotechnology · doi:10.1385/mb:24:2:127 · Cited by 4
Modification of globin gene expression by RNA targeting strategies
Shen, T.-J., Rogers, H. M., Yu, X., Lin, F., Noguchi, C. T., & Ho, C. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.05.003 · Cited by 4
The Advent of Lentiviral Vectors: Prospects for Cancer Therapy
Sadelain, M., & Rivière, I. (2002) · Elsevier eBooks · doi:10.1016/b978-012437551-2/50007-0 · Cited by 4
Self-citationHaematological Diseases in the Tropics
Thachil, J. V., Mbanya, D., & Bates, I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-7959-7.00069-5 · Cited by 4
Noguchi, C. T., Schechter, A. N., Haley, J. D., & Abraham, D. J. (2003) · Wiley eBooks · doi:10.1002/0471266949.bmc050 · Cited by 4
Dong, W.-J., Wu, X., Liu, D., Li, J., Liu, G., Zu, Z.-X., Zhao, N., Hou, Y., & Liang, C. (2002) · Journal of Biomedical Science · doi:10.1007/bf02256072 · Cited by 4
Globin Gene Therapy: One (Seemingly) Small Vector Change, One Giant Leap in Optimism
Bodine, D. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0113 · Cited by 4
Dennis-Antwi, J. (2006) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 4
Mistry, A., Tanga, S., & Maji, B. (2023) · Springer eBooks · doi:10.1007/978-981-19-8520-1_11 · Cited by 3
Brooks, J. F., Davies, J. M., Wells, J. W., & Steptoe, R. J. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1611-8 · Cited by 3
PATHOPHYSIOLOGY OF HEMOGLOBIN AND ITS DISORDERS
Steinberg, M. H. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511596582.012 · Cited by 3
Breveglieri, G., Salvatori, F., Finotti, A., Cosenza, L. C., Zuccato, C., Bianchi, N., Breda, L., Rivella, S., Bresciani, A., Bisbocci, M., et al. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01959-z · Cited by 3
“Stefano Rivella (Hematology Division, Children’s Hospital of Philadelphia, USA), who studied it for the β-globin gene transfer in gene therapy in murine models of β-thalassemia [37].”
BackgroundSelf-citationGene Therapy for Erythroid Metabolic Inherited Diseases
García-Gómez, M., Bustamante, O. Q., García, M., Navarro, S., Garate, Z., & Jose, C. (2013) · InTech eBooks · doi:10.5772/52531 · Cited by 3
Stem Cell Transplantation and Gene Therapy in utero
Surbek, D., Schatt, S., & Holzgreve, W. (2001) · Transfusion Medicine and Hemotherapy · doi:10.1159/000050228 · Cited by 3
Hematopoietic Cell Transplantation for Thalassemia
Lucarelli, G., & Gaziev, J. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch71 · Cited by 3
Inherited Hemoglobin Disorders
Munshi, A. (2015) · InTech eBooks · doi:10.5772/59742 · Cited by 3
Worgall, S., & Crystal, R. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00029-0 · Cited by 3
Hematopoietic stem cell gene therapy
Thrasher, A. J., & Candotti, F. (2005) · Wiley eBooks · doi:10.1002/047001153x.g107206 · Cited by 3
Bringing Gene Therapy to the Clinic
Ball, B. G., & Anderson, W. F. (2000) · JAMA · doi:10.1001/jama.284.21.2788-jms1206-5-1 · Cited by 3
Davies, N., Freebody, J., & Murray, V. (2004) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2004.04.002 · Cited by 3
Globin gene transfer as a potential treatment for the β‐thalassaemias and sickle cell disease
Sadelain, M. (2004) · Vox Sanguinis · doi:10.1111/j.1741-6892.2004.00495.x · Cited by 3
Self-citationAthanassiadou, A., Sgourou, A., & Verras, M. (2025) · Human Gene Therapy · doi:10.1089/hum.2025.034 · Cited by 2
Gao, Z.-Y., Yang, Z.-X., Deng, D.-H., Zhang, F., Yu, B., Zhang, Y., Lv, X., Nakamura, Y., Gong, A., Cheng, T., et al. (2025) · Blood Science · doi:10.1097/bs9.0000000000000253 · Cited by 2
“17,18 19–22 While CRISPR editing shows promise, long-term genotoxicity and off-target effects remain under active investigation.”
Current Status and Developments in Gene Therapy for Thalassemia and Sickle Cell Disease
Yannaki, E., & Karponi, G. (2014) · Thalassemia Reports · doi:10.4081/thal.2014.4876 · Cited by 2
Fetal Treatment of Genetic Disorders
Nguyen, Q.-H. L., Witt, R. G., & MacKenzie, T. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53094-1.00016-3 · Cited by 2
Gene therapy and editing in the treatment of hereditary blood disorders: Medical and ethical aspects
Alburquerque, P. C., Gómez‐Tatay, L., & Aznar, J. (2021) · Clinical Ethics · doi:10.1177/14777509211057255 · Cited by 2
A Journey from Blood Cells to Genes and Back
Luzzatto, L. (2023) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-101022-105018 · Cited by 2
Self-citationThe impact of hematopoietic stem cell transplantation on the management of thalassemia
Isgrò, A., Marziali, M., Sodani, P., Gaziev, J., & Lucarelli, G. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.14 · Cited by 2
Human Gene Therapy with Retrovirus and Lentivirus Vectors
Kochan, G. T., Stephenson, H. N., Breckpot, K., & Escors, D. (2012) · SpringerBriefs in biochemistry and molecular biology · doi:10.1007/978-3-0348-0402-8_6 · Cited by 2
Stem Cell Transplantation for Hemoglobinopathies
Wu, C. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-438-4_11 · Cited by 2
Russell, S. J., & Peng, K. W. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50097-4 · Cited by 2
Viral‐Mediated Delivery of shRNA and miRNA
Manfredsson, F. P. (2013) · Wiley eBooks · doi:10.1002/9781118610749.ch11 · Cited by 2
Cheng, J. C., Horwitz, E. M., Karsten, S. L., Shoemaker, L. D., Kornblumc, H. I., Malik, P., & Sakamoto, K. M. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0397 · Cited by 2
Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin
Nègre, O., Fusil, F., Henri, A., Villette, J., Leboulch, P., Beuzard, Y., & Payen, E. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2007.12.004 · Cited by 2
Müller, L., Milsom, M. D., & Williams, D. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7656-7_6 · Cited by 2
Philippe, S. (2007) · HAL · Cited by 2
Clinical Trials of Gene Marking and Gene Therapy Using Hematopoietic Stem Cells
Kohn, D. B., & Crooks, G. M. (2003) · Wiley eBooks · doi:10.1002/9780470987070.ch11 · Cited by 2
Gene Therapy for Severe Haemoglobin Disorders
Villamizar, O., Chambers, C. B., & Wilber, A. C. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0025829 · Cited by 2
Averting abnormal inheritance: potential of gene therapy and preimplantation diagnosis
Thrasher, A. J., & Edward, R. G. (2004) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60503-2 · Cited by 2
Lovett, J. (2018) · CUNY Academic Works (City University of New York) · Cited by 2
Gene therapy for sickle cell disease
Olowoyeye, A., & Okwundu, C. I. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007652 · Cited by 2
Davis, B. R., & Prokopishyn, N. L. (2004) · Elsevier eBooks · doi:10.1016/b978-012436643-5/50162-0 · Cited by 1
Physiologically-Regulated Expression Vectors for Gene Therapy
Hibbitt, O., & Wade‐Martins, R. (2011) · InTech eBooks · doi:10.5772/21752 · Cited by 1
“In mice expressing the ┚-globin from a cDNA expression plasmid without the locus control region, low levels of protein are detected with no tissue-specificity (Magram et al. 1985; May et al. 2000; Vadolas et al. 2005).”
BackgroundAddressing the envelope for gene delivery
O’Reilly, R. J. (2012) · Blood · doi:10.1182/blood-2012-09-451476 · Cited by 1
Wang, P., Xie, S., Chi, Y., Jiao, F., Li, Z., Ma, Y., & Liu, F. (2009) · Biologia · doi:10.2478/s11756-009-0141-4 · Cited by 1
“…such as increasing β-globin expression by antisense RNA restoring abnormal splicing transcription (Vacek et al. 2003), genetic manipulation in autologous hematopoietic stem cells (May et al. 2000, 2002), and gene transfer com- bined with RNA interference technologies (Samakoglu et al. 2006).”
BackgroundGene and Cell Therapy Involving Hematopoietic Stem Cell
André‐Schmutz, I., & Cavazzana, M. (2006) · Springer eBooks · doi:10.1007/978-0-387-33535-3_12 · Cited by 1
Yao, H., Chen, H., Huang, L., Shen, Q., Jia, W., & Xue, J. (2006) · Frontiers in Biology · doi:10.1007/s11515-006-0016-9 · Cited by 1
Léger, C. (2000) · Biofutur · doi:10.1016/s0294-3506(00)80107-6 · Cited by 1
Metadata
- Authors
- May, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, San Francisco (US)
- Corresponding author
- Sadelain, Michel
- Venue
- Nature
- Published
- 2000-07
- Volume
- 406
- Issue
- 6791
- Pages
- 82-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1997170085
- Cited by
- 567
- References
- 34
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 11 · 2022: 11 · 2021: 10 · 2020: 10 · 2019: 16 · 2018: 26 · 2017: 18 · 2016: 16 · 2015: 15 · 2014: 13 · 2013: 22 · 2012: 24
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- James S. McDonnell Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- beta-thalassemia, sickle cell disease, lentiviral transduction, human beta-globin gene, hematopoietic stem cells, locus control region, hemoglobin synthesis, anemia, erythrocyte morphology, position effect, transcriptional silencing
- MeSH terms
- Animals, Cell Line, Female, Genetic Vectors, Globins, Hemoglobins, Humans, Male, Recombinant Proteins, Transduction, Genetic, Genetic Therapy, HIV-1, Bone Marrow Transplantation, Lentivirus, beta-Thalassemia, Gene Transfer Techniques, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.